Methods to analyse cost data of patients who withdraw in a clinical trial setting.

PubWeight™: 1.14‹?› | Rank: Top 10%

🔗 View Article (PMID 14596629)

Published in Pharmacoeconomics on January 01, 2003

Authors

Jan B Oostenbrink1, Maiwenn J Al, Maureen P M H Rutten-van Mölken

Author Affiliations

1: Institute for Medical Technology Assessment, Erasmus Medical Centre Rotterdam, 3000 DR Rotterdam, PO Box 1738, Rotterdam, The Netherlands. oostenbrink@bmg.eur.nl

Articles citing this

Societal costs and quality of life of children suffering from attention deficient hyperactivity disorder (ADHD). Eur Child Adolesc Psychiatry (2007) 1.34

Economic evaluation of dose-response resistance training in older women: a cost-effectiveness and cost-utility analysis. Osteoporos Int (2010) 1.05

Economic evaluations: a new avenue of outcome assessment in spinal disorders. Eur Spine J (2005) 0.93

Assessment of progression of COPD: report of a workshop held in Leuven, 11-12 March 2004. Thorax (2005) 0.91

The effectiveness of early lens extraction with intraocular lens implantation for the treatment of primary angle-closure glaucoma (EAGLE): study protocol for a randomized controlled trial. Trials (2011) 0.91

Randomised controlled trial of tailored interventions to improve the management of anxiety and depressive disorders in primary care. Implement Sci (2011) 0.85

Collaborative stepped care for anxiety disorders in primary care: aims and design of a randomized controlled trial. BMC Health Serv Res (2009) 0.83

Effectiveness of computer-navigated minimally invasive total hip surgery compared to conventional total hip arthroplasty: design of a randomized controlled trial. BMC Musculoskelet Disord (2007) 0.83

Multiple imputation strategies for zero-inflated cost data in economic evaluations: which method works best? Eur J Health Econ (2015) 0.79

Cost-effectiveness analysis of cognitive behaviour therapy for treatment of minor or mild-major depression in elderly patients with type 2 diabetes: study protocol for the economic evaluation alongside the MIND-DIA randomized controlled trial (MIND-DIA CEA). BMC Geriatr (2009) 0.77

Sustained economic benefits of resistance training in community-dwelling senior women. J Am Geriatr Soc (2011) 0.76

Mobility Is a Key Predictor of Change in Well-Being Among Older Adults Who Experience Falls: Evidence From the Vancouver Falls Prevention Clinic Cohort. Arch Phys Med Rehabil (2015) 0.75

A method to estimate off-schedule observations in a longitudinal study. Ann Epidemiol (2011) 0.75

Within-trial economic evaluation of diabetes-specific cognitive behaviour therapy in patients with type 2 diabetes and subthreshold depression. BMC Public Health (2010) 0.75

Challenges with cost-utility analyses of behavioural interventions among older adults at risk for dementia. Br J Sports Med (2013) 0.75

Action seniors! - secondary falls prevention in community-dwelling senior fallers: study protocol for a randomized controlled trial. Trials (2015) 0.75

Mobility predicts change in older adults' health-related quality of life: evidence from a Vancouver falls prevention prospective cohort study. Health Qual Life Outcomes (2015) 0.75

Economic evaluation of aerobic exercise training in older adults with vascular cognitive impairment: PROMoTE trial. BMJ Open (2017) 0.75

Articles by these authors

Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med (2011) 7.92

An official American Thoracic Society/European Respiratory Society statement: key concepts and advances in pulmonary rehabilitation. Am J Respir Crit Care Med (2013) 4.49

Cost effectiveness of physiotherapy, manual therapy, and general practitioner care for neck pain: economic evaluation alongside a randomised controlled trial. BMJ (2003) 2.80

Probabilistic Markov model to assess the cost-effectiveness of bronchodilator therapy in COPD patients in different countries. Value Health (2005) 2.32

Optimizing a portfolio of health care programs in the presence of uncertainty and constrained resources. Soc Sci Med (2003) 2.01

Cost-effectiveness of face-to-face smoking cessation interventions: a dynamic modeling study. Value Health (2005) 1.93

Influenza vaccination in children with asthma: randomized double-blind placebo-controlled trial. Am J Respir Crit Care Med (2003) 1.81

Are GOLD ABCD groups better associated with health status and costs than GOLD 1234 grades? A cross-sectional study. Prim Care Respir J (2014) 1.49

If you try to stop smoking, should we pay for it? The cost-utility of reimbursing smoking cessation support in the Netherlands. Addiction (2010) 1.42

Long-term effectiveness and cost-effectiveness of smoking cessation interventions in patients with COPD. Thorax (2010) 1.39

Real-life compliance and persistence among users of subcutaneous and sublingual allergen immunotherapy. J Allergy Clin Immunol (2013) 1.36

The analysis of incomplete cost data due to dropout. Health Econ (2005) 1.35

Resource use and risk factors in high-cost exacerbations of COPD. Respir Med (2004) 1.28

Towards integrated care for chronic conditions: Dutch policy developments to overcome the (financial) barriers. Health Policy (2010) 1.19

Improving model validation in health technology assessment: comments on guidelines of the ISPOR-SMDM modeling good research practices task force. Value Health (2013) 1.18

Cost effectiveness of interventions for lateral epicondylitis: results from a randomised controlled trial in primary care. Pharmacoeconomics (2004) 1.16

The cost-utility of rotavirus vaccination with Rotarix (RIX4414) in the Netherlands. Vaccine (2007) 1.16

Exploring payment schemes used to promote integrated chronic care in Europe. Health Policy (2013) 1.10

Cost-effectiveness of varenicline compared with bupropion, NRT, and nortriptyline for smoking cessation in the Netherlands. Curr Med Res Opin (2008) 1.09

The health economic impact of disease management programs for COPD: a systematic literature review and meta-analysis. BMC Pulm Med (2013) 1.05

Severity distribution of chronic obstructive pulmonary disease (COPD) in Dutch general practice. Respir Med (2006) 1.03

Cost-effectiveness of temozolomide for the treatment of newly diagnosed glioblastoma multiforme: a report from the EORTC 26981/22981 NCI-C CE3 Intergroup Study. Cancer (2008) 0.99

Cost consequences of implementing an electronic decision support system for ordering laboratory tests in primary care: evidence from a controlled prospective study in the Netherlands. Clin Chem (2006) 0.96

Efficacy and costs of nutritional rehabilitation in muscle-wasted patients with chronic obstructive pulmonary disease in a community-based setting: a prespecified subgroup analysis of the INTERCOM trial. J Am Med Dir Assoc (2010) 0.96

A microcosting study of intensive care unit stay in the Netherlands. J Intensive Care Med (2008) 0.94

Surgery is more cost-effective than splinting for carpal tunnel syndrome in the Netherlands: results of an economic evaluation alongside a randomized controlled trial. BMC Musculoskelet Disord (2006) 0.94

Does the 2013 GOLD classification improve the ability to predict lung function decline, exacerbations and mortality: a post-hoc analysis of the 4-year UPLIFT trial. BMC Pulm Med (2014) 0.92

Revisiting the decision rule of cost-effectiveness analysis under certainty and uncertainty. Soc Sci Med (2003) 0.89

RECODE: design and baseline results of a cluster randomized trial on cost-effectiveness of integrated COPD management in primary care. BMC Pulm Med (2013) 0.87

Crossing borders: factors affecting differences in cost-effectiveness of smoking cessation interventions between European countries. Value Health (2009) 0.86

Self-report versus care provider registration of healthcare utilization: impact on cost and cost-utility. Int J Technol Assess Health Care (2009) 0.86

Effectiveness and cost-effectiveness of early assisted discharge for chronic obstructive pulmonary disease exacerbations: the design of a randomised controlled trial. BMC Public Health (2010) 0.86

Expected value of perfect information: an empirical example of reducing decision uncertainty by conducting additional research. Value Health (2008) 0.86

Developing and applying a stochastic dynamic population model for chronic obstructive pulmonary disease. Value Health (2011) 0.85

Continuous versus intermittent data collection of health care utilization. Med Decis Making (2013) 0.84

Early assisted discharge with generic community nursing for chronic obstructive pulmonary disease exacerbations: results of a randomised controlled trial. BMJ Open (2012) 0.83

Patient preference and satisfaction in hospital-at-home and usual hospital care for COPD exacerbations: results of a randomised controlled trial. Int J Nurs Stud (2013) 0.82

Is the EQ-5D responsive to recovery from a moderate COPD exacerbation? Respir Med (2011) 0.82

The road not taken: transferability issues in multinational trials. Pharmacoeconomics (2013) 0.81

Portfolio theory and cost-effectiveness analysis: a further discussion. Value Health (2004) 0.81

e-Monitoring of Asthma Therapy to Improve Compliance in children using a real-time medication monitoring system (RTMM): the e-MATIC study protocol. BMC Med Inform Decis Mak (2013) 0.81

Portfolio theory and the alternative decision rule of cost-effectiveness analysis: theoretical and practical considerations. Soc Sci Med (2004) 0.81

The role of value-of-information analysis in a health care research priority setting: a theoretical case study. Med Decis Making (2012) 0.78

Cost-effectiveness of early assisted discharge for COPD exacerbations in The Netherlands. Value Health (2013) 0.78

Adjusting for COPD severity in database research: developing and validating an algorithm. Int J Chron Obstruct Pulmon Dis (2011) 0.78

Does influenza vaccination exacerbate asthma in children? Vaccine (2004) 0.78

Largely ignored: the impact of the threshold value for a QALY on the importance of a transferability factor. Eur J Health Econ (2010) 0.78

Cost-effectiveness of tiotropium versus salmeterol: the POET-COPD trial. Eur Respir J (2012) 0.77

A choice that matters? Smulation study on the impact of direct meta-analysis methods on health economic outcomes. Pharmacoeconomics (2013) 0.77

Inverse probability weighting to control for censoring in a post hoc analysis of quality-adjusted survival data from a clinical trial of temsirolimus for renal cell carcinoma. J Med Econ (2011) 0.77

The cost utility of solifenacin in the treatment of overactive bladder. Int Urol Nephrol (2008) 0.76

Conclusion on cost-effectiveness of rotavirus vaccination highly dependent on assumptions. Vaccine (2009) 0.76

Optimising the performance of an outpatient setting. Swiss Med Wkly (2004) 0.75

An economic evaluation of budesonide/formoterol for maintenance and reliever treatment in asthma in general practice. Adv Ther (2009) 0.75

A risk-adjusted approach to comparing the return on investment in health care programs. Int J Health Care Finance Econ (2004) 0.75